Angiotensin-converting Enzyme Inhibitor Radionuclide Renogram – A Non-invasive Tool to Suspect Renovascular Hypertension

Angiotensin-converting Enzyme Inhibitor

The hemodynamic effects of an oral angiotensin-converting enzyme inhibitor, captopril, were evaluated in 10 symptomatic patients with chronic congestive heart failure. In all patients there was a significant increase in cardiac output (average 28%), stroke volume (49%), and stroke work index (26%), along with a decrease in pulmonary capillary wedge pressure (48%), indicating improved left ventr...

Angiotensin-converting Enzyme Inhibitor

The effects of angiotensin-converting enzyme inhibitor (CEI) SQ14225 on infarct size and regional myocardial blood flow were studied in 21 anesthetized dogs subjected to 6 hours of coronary occlusion. An area of myocardium at risk of necrosis was determined in vivo after 15 minutes of coronary occlusion but before CEI treatment (AR1) using an autoradiographic technique and after treatment after...

Angiotensin Converting Enzyme in Sarcoidosis

When to Suspect for Renovascular Hypertension

Renovascular hypertension (RVH) is the most important cause of secondary hypertension and it is often due to occlusive lesion of renal arteries. RVH is precipitated by a hemodynamically significant stenosis of a renal artery or arteries (that is, a stenosis greater than 75% of the vessel lumen or 50% with poststenotic dilation). The frequency of renovascular hypertension is less than 1% in pati...

Trandolapril: a newer angiotensin-converting enzyme inhibitor.

BACKGROUND Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or symptoms of chronic heart failure within the first 2 days after an acute myocardial infarction (AMI). The fixed-dose combination...